Jefferies Sees Upside to Stemline Therapeutics (STML) SL-401 Timeline

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Jefferies Sees Upside to Stemline Therapeutics (STML) SL-401 Timeline

Aegis Capital Adjusts PT on Stemline (STML) to $55 Following Financing, Development Update

January 30, 2015 9:49 AM EST

Aegis Capital lowers its price target on Stemline Therapeutics (Nasdaq: STML) from $68 to $55 and maintains a Buy rating on the stock following a recent financing round and development update.

Analyst Yi Chen commented, Stemline Therapeutics recently announced that it had licensed from... More

Stemline Therapeutics' (STML) SL-701 Receives FDA Orphan Designation as Glioma Treatment

January 30, 2015 8:43 AM EST

Stemline Therapeutics (NASDAQ: STML) announced that SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.

SL-701 is an enhanced immunotherapy designed to activate the immune system to kill malignant gliomas, which are aggressive malignancies of the brain that... More